Loading
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Previous close
$2.59
+$0.02 · +0.78%
Regular session · ET · Market data may be delayed.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Day range
Current $2.59
52-week range
Current $2.59
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
85
Deep Value
Sentiment
58
Mixed
Risk
55
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Day range
Current $2.59
52-week range
Current $2.59
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 206.13M USD | 180.27M USD | 156.37M USD | 162.05M USD | 130.86M USD |
| Cost of goods sold | 93.85M USD | 80.75M USD | 69.97M USD | 74.95M USD | 63.48M USD |
| Gross profit | 112.29M USD | 99.52M USD | 86.4M USD | 87.09M USD | 67.38M USD |
| Research and development | 67.72M USD | 58.91M USD | 67.64M USD | 64.11M USD | 63.69M USD |
| Selling, general, and administrative | 80.91M USD | 75.89M USD | 75.52M USD | 83.34M USD | 81.29M USD |
| Operating expenses | 120.97M USD | 113.75M USD | 116.45M USD | 121.18M USD | 116.32M USD |
| Interest expense | 8.34M USD | 8.88M USD | 8.39M USD | 5.83M USD | 4.92M USD |
| Depreciation and amortization | 1.43M USD | 1.86M USD | 2.6M USD | 2.98M USD | 3.15M USD |
| Operating income | −8.68M USD | −14.23M USD | −30.05M USD | −34.08M USD | −48.94M USD |
| Net income | −15.63M USD | −20.92M USD | −37.49M USD | −42.78M USD | −54.37M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.00
54.44% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK22.67M0.34%5.56B USD0.75%$86.22-1.06%
ARK Genomic Revolution ETFARKG20.23M1.01%1.56B USD0.75%$47.14-0.13%
iShares Russell 2000 ETFIWM13.32M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI13.06M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF4.97M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO4.85M0.03%14.58B USD0.24%$377.54+0.12%
Fidelity Enhanced Small Cap ETFFESM4.23M0.06%6.03B USD0.28%$47.36+0.21%
iShares U.S. Small-Cap Equity Factor ETFSMLF2.89M0.07%4.26B USD0.15%$88.15+0.20%ARK Innovation ETFARKKARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMiShares U.S. Small-Cap Equity Factor ETFSMLFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
